NFKB1 and neoplasm: Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, induced NFkB activation, making the cells more vulnerable for NFkB inhibition, and also induced pro-apoptotic Bax expression in TNBC which resulted in a synergistic anti-tumor activity in vitro and in vivo with BTZ [109].